Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)

• Status: Completed
• Trial end date: 2020-12-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the gametocytocidal and transmission reducing activity of dihydroartemisinin-piperaquine (DP) with and without various low doses of tafenoquine (TQ; 1.66mg/kg, 0.83mg/kg, or 0.415mg/kg). Outcome measures will include infectivity to mosquitoes at 2 and 7 days after treatment, gametocyte density throughout follow-up, and safety measures including haemoglobin density.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: London School of Hygiene and Tropical Medicine
• Treatments: Artenimol; Dihydroartemisinin; Piperaquine; Tafenoquine

Criteria

Inclusion Criteria:

• Age ≥ 12 years and ≤ 50 years

• Glucose 6 phosphate dehydrogenase (G6PD) normal status defined by Carestart rapid diagnostic test or the G6PD qualitative test (OSMMR2000)

• Absence of symptomatic falciparum malaria, defined by fever on enrolment

• Presence of P. falciparum gametocytes on thick blood film at a density >16 gametocytes/µL (i.e. ≥ gametocytes recorded in the thick film against 500 white blood cells)

• Absence of other non-P. falciparum species on blood film

• No allergies to study drugs

• No use of antimalarial drugs over the past 7 days (as reported by the participant)

• Hemoglobin ≥ 10 g/dL

• Individuals weighing < = 80 kg

• No evidence of acute severe or chronic disease

• Written, informed consent

Exclusion Criteria:

• Age < 12 years or > 50 years

• Women who are pregnant or lactating

• Blood thick film negative for sexual stages of malaria

• Detection of a non-P. falciparum species by microscopy

• Previous reaction to study drugs / known allergy to study drugs

• Signs of severe malaria, including hyperparasitemia (defined as asexual parasitemia > 100,000 parasites / µL)

• Signs of acute or chronic illness, including hepatitis

• The use of other medication (with the exception of paracetamol and/or aspirin)

• Consent not given

• G6PD-deficiency by Carestart rapid diagnostic test or the OSMMR2000 G6PD qualitative test

• Use of antimalarial drugs over the past 7 days (as reported by the participant)

• The use of other medication (with the exception of paracetamol and/or aspirin)

• Clinically significant illness (intercurrent illness e.g. pneumonia, pre-existing condition e.g. renal disease, malignancy or conditions that may affect absorption of study medication e.g. severe diarrhea or any signs of malnutrition as defined clinically)

• Signs of hepatic injury (such as nausea and/or abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child Pugh stage B or C)

• Signs, symptoms or known renal impairment

• Clinically significant abnormal laboratory values as determined by history, physical examination or routine blood chemistries and hematology values (laboratory guideline values for exclusion are hemoglobin < 10 g/dL, platelets < 50,000/μl, White Blood Cell count (WBC) < 2000/μl, serum creatinine >2.0mg/dL, or ALT or AST more than 3 times the upper limit of normal for age.

• Family history of diseases leading to QT prolongation or recent treatment with drugs linked to QT prolongation

• Blood transfusion in the last 90 days.

• Consistent with the long half-life of tafenoquine, effective contraception should be continued for 5 half-lives (3 months) after the end of treatment.

• History of psychiatric disorders